

Claim 25 has been added. Support for Claim 25 may be found, for example, at Page 18, lines 6-8 of the application. Accordingly, the new claim is fully supported by the specification.

Claims 6-8, 10, 19 and 20 have been amended to correct their dependencies in view of the cancellation of claims (e.g., Claim 1) and the addition of Claim 25. Accordingly, the claim amendments are fully supported.

Claims 6-8, 10-22 and 25 will remain after amendment.

Election/Restriction

The Office states that the Applicants are required under PCT Rule 13.1 to elect a single inventive concept selected from the following groups:

- 2.I. Claims 1-22, drawn to variants of KGF-2, polynucleotides encoding said variants, vectors comprising said polynucleotides, host cells transfected with said vectors and a method of producing said variants.
- 2.II. Claims 23-24, drawn to a method of stimulating the production of epithelial cells, comprising contacting such cells with an effective amount of a variant of KGF-1.

In response to a restriction requirement, Applicants' attorney hereby elects to prosecute the invention of Group 2.I., drawn to variants of KGF-2, polynucleotides encoding said variants, vectors comprising said polynucleotides, host cells transfected with said vectors and a method of producing said variants.

Subsequent to the "Notice to Comply ...", furnished to Applicants' Attorney via facsimile on July 27, 2000 (see Exhibit A), please note that Applicants have previously submitted such requested sequence diskette, hard copy of sequence listing and Attorney statement, the receipt of which was acknowledged by the USPTO on the attached Postcard (Exhibit B). Applicants hereby enclose a substitute Attorney Statement, and diskette and paper copy of the sequence listing for the Examiner's convenience.

The present application is in condition for allowance, and an early notification to that effect is earnestly solicited.



09/284,100

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "T. D. Zindrick".

Thomas D. Zindrick

Attorney/Agent for Applicant

Registration No.: 32,185

Phone: (805) 447-8101

Date: September 11, 2000

Please send all future correspondence to:

U.S. Patent Operations/TDZ

Dept. 430, M/S 27-4-A

AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1799



EXHIBIT A

U. S. PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20031RECEIVED
SEP 26 2000

TELECOPY / FACSIMILE TRANSMISSION

TECH CENTER 1600/2000

Date:

7/27/00

Total 2 pages, including cover sheet.

To: T. Zindrizek

[ATTORNEY, AGENT,
FIRM, OR AGENCY]

Re: Sequence compliance notice

[ATTORNEY'S DOCKET NUMBER
OR APPLICATION NUMBER]

FAX/ 805 / 499-8011

Telecopier number:

From:

Fozia Hamud 1646
Patent Examiner, Art Unit 1812

Tel.

(703) 308-8896

Fax

(703) 308-0294

Message:

I am Faxing you notice to comply with requirements
for applications containing nucleotide sequences and/or
amino acid sequence disclosures.

GROUP 1800 FAX NUMBERS

Group Director (703) 305-3014	Art Unit 1805 (703) 308-0294	Art Unit 1812 (703) 308-0294
Biotech. Specialists 305-3014	1806 308-4065	1813 305-7939
Art Unit 1802 308-4065	1807 305-7401	1814 305-7401
1803 308-4227	1808 308-7401	1816 305-7939
1804 308-0294	1811 305-3014	

All of the above fax machines are available to receive transmissions 24 hours/day, 7 days/week.

If you have not received all of the pages of this transmission, please contact the Examiner by telephone as indicated above.

In compliance with 1096 OG 30, the filing date accorded each official transmission received by the PTO will be determined by the fax machine's stamped date found on the last page of the transmission, unless that date is a Saturday, Sunday, or federal holiday within the District of Columbia, in which case the official date of receipt will be the next business day.

This transmission is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you are not the intended recipient or the employee or agent responsible for delivering this transmission to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original transmission via the U.S. Postal Service to: Group 1800, U.S. Patent and Trademark Office, Crystal Mall 1, Arlington, VA 22202. Thank you.

Application No. 09/284,100

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821.825. Applicant's attention is directed to these regulations, published at 114 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.



EXHIBIT B

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND RETURNING THIS POST CARD

APPLICANTS: Linda Owers Narhi and Timothy David Osslund
SERIAL NO.: To Be Assigned
FILED: Herewith
TITLE: KERATINOCYTE GROWTH FACTOR-2 PRODUCTS

DOCUMENTS:

418 Rec'd PCT/PTO 07 APR 1999
2 pp Transmittal Letter
2 pp Combined Declaration for Patent Application and Power of Attorney
4 pp Recordation Form Cover Sheet w/ Assignment
17 pp Attorney Statement with paper copy of sequence listing
1 Sequence Disk

09/284100

DOCKET NO. A-423C

Mailed: April 7, 1999

Attorney: Thomas D. Zindrick

Express Mail No. EL198792922US